PAI Pharma ("PAI"), a portfolio company of Olympus Partners and a leading U.S. developer, manufacturer and marketer of oral liquid medicines, today announced the acquisition of Nivagen Pharmaceuticals ...
Stablepharma Ltd R&D Centre, Madrid, Spain Stablepharma and AFT Pharmaceuticals partner to address multi-billion dollar ...
Stablepharma and AFT Pharmaceuticals partner to address multi-billion dollar anti-infective and oncology therapeutics market ...
NDTV Profit on MSN
Stock Picks Today: ICICI Lombard, Info Edge, Tata Steel And More On Brokerages’ Radar
They have also shared an outlook on pharma, telecom, internet platforms, banking, metals and consumer sectors, alongside ...
TipRanks on MSN
Caplin Point buys $473 million portfolio of US-approved injectable and ophthalmic ANDAs
Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) has shared an update. Caplin Point Laboratories, through its subsidiaries Caplin Steriles ...
Importantly, a clinician should also ask about your mental health before prescribing a GLP-1. If you have a history of ...
Proponents say these facilities offer easy access to aesthetic procedures such as Botox and fillers. Detractors insist ...
Learn more about whether Harrow, Inc. or Ligand Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...
About SHINE Technologies, LLC Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, ...
EQB announces renewal of Normal Course Issuer Bid and Approval of Automatic Securities Purchase Plan
EQB Inc. (the "Company") announced today that it has received approval from the Toronto Stock Exchange (the "TSX") to renew its Normal Course Issuer Bid (the "NCIB") for an additional 12-month period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback